Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

723 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial.
Hoen B, Fournier I, Lacabaratz C, Burgard M, Charreau I, Chaix ML, Molina JM, Livrozet JM, Venet A, Raffi F, Aboulker JP, Rouzioux C; PRIMSTOP Study Group. Hoen B, et al. Among authors: raffi f. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):307-16. doi: 10.1097/01.qai.0000182628.66713.31. J Acquir Immune Defic Syndr. 2005. PMID: 16249705 Clinical Trial.
Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.
Le Moing V, Peytavin G, Journot V, Cottalorda J, Bouvet E, Chêne G, Préau M, de Boever CM, Leport C, Raffi F; Antiprotease Cohort (APROCO) Study Group. Le Moing V, et al. Among authors: raffi f. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):497-9. doi: 10.1097/00126334-200312150-00008. J Acquir Immune Defic Syndr. 2003. PMID: 14657760
Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.
Allavena C, Ferré V, Brunet-François C, Delfraissy JF, Lafeuillade A, Valantin MA, Bentata M, Michelet C, Poizot-Martin I, Dailly E, Launay O, Raffi F; Bitherapy Kaletra-Sustiva Study Group. Allavena C, et al. Among authors: raffi f. J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):300-6. doi: 10.1097/01.qai.0000165914.42827.bb. J Acquir Immune Defic Syndr. 2005. PMID: 15980689 Clinical Trial.
Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
Delaugerre C, Peytavin G, Dominguez S, Marcelin AG, Duvivier C, Gourlain K, Amellal B, Legrand M, Raffi F, Costagliola D, Katlama C, Calvez V. Delaugerre C, et al. Among authors: raffi f. J Med Virol. 2005 Nov;77(3):345-50. doi: 10.1002/jmv.20462. J Med Virol. 2005. PMID: 16173015 Clinical Trial.
Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase.
Carrieri MP, Leport C, Protopopescu C, Cassuto JP, Bouvet E, Peyramond D, Raffi F, Moatti JP, Chêne G, Spire B. Carrieri MP, et al. Among authors: raffi f. J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):477-85. doi: 10.1097/01.qai.0000186364.27587.0e. J Acquir Immune Defic Syndr. 2006. PMID: 16652057
723 results